MX358149B - Derivado de pirazoloquinolina. - Google Patents
Derivado de pirazoloquinolina.Info
- Publication number
- MX358149B MX358149B MX2014003800A MX2014003800A MX358149B MX 358149 B MX358149 B MX 358149B MX 2014003800 A MX2014003800 A MX 2014003800A MX 2014003800 A MX2014003800 A MX 2014003800A MX 358149 B MX358149 B MX 358149B
- Authority
- MX
- Mexico
- Prior art keywords
- hydrogen atom
- pde9
- acceptable salt
- formula
- inhibitory effect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto representado por la fórmula (I) o una de sus sales farmacéuticamente aceptables que ejerce un efecto inhibitorio sobre PDE9 y, por lo tanto, cabe esperar que sea capaz de incrementar el nivel de cGMP en el cerebro. Debido a que el efecto inhibitorio sobre PDE9 y un aumento en el nivel de cGMP contribuyen a mejorar el comportamiento de aprendizaje y memoria, el compuesto mencionado anteriormente o una de sus sales farmacéuticamente aceptables estaría disponible como remedio para la disfunción cognitiva en zzzzzla enfermedad de Alzheimer. En la fórmula (I): R1 representa un átomo de hidrógeno; R2 representa un grupo de anillo aromático, etc.; R3 representa un átomo de hidrógeno, etc.; R4 representa un átomo de hidrógeno; R5 representa un grupo oxepanilo, etc.; y R6 representa un átomo de hidrógeno. (ver Fórmula).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161544860P | 2011-10-07 | 2011-10-07 | |
US201161550623P | 2011-10-24 | 2011-10-24 | |
US201161558110P | 2011-11-10 | 2011-11-10 | |
US201161580903P | 2011-12-28 | 2011-12-28 | |
PCT/JP2012/075748 WO2013051639A1 (ja) | 2011-10-07 | 2012-10-04 | ピラゾロキノリン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014003800A MX2014003800A (es) | 2014-07-28 |
MX358149B true MX358149B (es) | 2018-08-07 |
Family
ID=48043792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014003800A MX358149B (es) | 2011-10-07 | 2012-10-04 | Derivado de pirazoloquinolina. |
Country Status (33)
Country | Link |
---|---|
US (2) | US8563565B2 (es) |
EP (1) | EP2769980B1 (es) |
JP (1) | JP5546693B2 (es) |
KR (1) | KR101943680B1 (es) |
CN (1) | CN103930423B (es) |
AR (1) | AR088235A1 (es) |
AU (1) | AU2012319549B2 (es) |
BR (1) | BR112014007912B1 (es) |
CA (1) | CA2861795C (es) |
CL (1) | CL2014000821A1 (es) |
CO (1) | CO6910200A2 (es) |
CY (1) | CY1117427T1 (es) |
DK (1) | DK2769980T3 (es) |
ES (1) | ES2568015T3 (es) |
HK (1) | HK1199018A1 (es) |
HR (1) | HRP20160273T1 (es) |
HU (1) | HUE028555T2 (es) |
IL (1) | IL231650A (es) |
IN (1) | IN2014CN02463A (es) |
JO (1) | JO3116B1 (es) |
ME (1) | ME02394B (es) |
MX (1) | MX358149B (es) |
MY (1) | MY167698A (es) |
PE (1) | PE20141557A1 (es) |
PL (1) | PL2769980T3 (es) |
RS (1) | RS54702B1 (es) |
RU (1) | RU2605096C2 (es) |
SG (1) | SG11201400717QA (es) |
SI (1) | SI2769980T1 (es) |
SM (1) | SMT201600108B (es) |
TW (1) | TWI562993B (es) |
WO (1) | WO2013051639A1 (es) |
ZA (1) | ZA201402439B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104703987B (zh) | 2011-10-10 | 2017-05-03 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
PE20151718A1 (es) * | 2013-04-05 | 2015-11-22 | Eisai Randd Man Co Ltd | Compuestos piridinilpirazoloquinolina |
ES2645149T3 (es) * | 2013-04-05 | 2017-12-04 | Eisai R&D Management Co., Ltd. | Sal de derivado de pirazoloquinolina y cristal de esta |
GB201406486D0 (en) | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
WO2016021192A1 (en) * | 2014-08-08 | 2016-02-11 | Eisai R&D Management Co., Ltd. | Process for production of (s)-(tetrahydrofuran-3-yl)hydrazine |
FI3865484T3 (fi) | 2015-07-07 | 2024-01-24 | H Lundbeck As | Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon |
WO2017046606A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds |
CN107056690A (zh) * | 2017-03-22 | 2017-08-18 | 上海康鹏科技有限公司 | 一种6‑溴吡啶‑3‑甲醛的制备方法 |
SG11201909590XA (en) | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
KR20200010211A (ko) * | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
US11833146B2 (en) * | 2017-06-01 | 2023-12-05 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
US11311530B2 (en) | 2017-06-01 | 2022-04-26 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
EP3743416B1 (en) * | 2018-01-23 | 2023-03-15 | Basf Se | Halogenation of pyridine derivatives |
FI3801526T3 (fi) | 2018-05-25 | 2024-03-20 | Cardurion Pharmaceuticals Inc | 6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja |
BR112021003686A2 (pt) * | 2018-08-31 | 2021-05-18 | Imara Inc. | inibidores de pde9 para tratar doença falciforme |
WO2020120673A1 (en) * | 2018-12-13 | 2020-06-18 | Intervet International B.V. | Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide |
CN113924290A (zh) | 2019-05-09 | 2022-01-11 | 范因斯坦医学研究院 | 硫代半肼基甲酸酯及其用途 |
US11471508B2 (en) | 2019-05-09 | 2022-10-18 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of diabetic peripheral neuropathy |
CN114126619B (zh) | 2019-05-09 | 2024-03-15 | 范因斯坦医学研究院 | 用于合成肽模拟物的化合物 |
US11883461B2 (en) | 2019-05-09 | 2024-01-30 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of severe sepsis |
WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
WO2021211864A1 (en) * | 2020-04-16 | 2021-10-21 | Incyte Corporation | Fused tricyclic kras inhibitors |
WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
WO2022002838A1 (de) | 2020-06-30 | 2022-01-06 | Bayer Aktiengesellschaft | Substituierte heteroaryloxypyridine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
US12077539B2 (en) | 2021-03-22 | 2024-09-03 | Incyte Corporation | Imidazole and triazole KRAS inhibitors |
WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
WO2023056421A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2426734C2 (ru) * | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
WO2005118583A1 (en) * | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
EP1925617B1 (en) * | 2005-09-15 | 2012-11-14 | ASKA Pharmaceutical Co., Ltd. | Heterocyclic compound, and production process and use thereof |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
US8299080B2 (en) * | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
WO2008139293A1 (en) | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
US8357688B2 (en) * | 2009-03-05 | 2013-01-22 | Astellas Pharma Inc. | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors |
ES2460019T3 (es) | 2009-03-31 | 2014-05-13 | Boehringer Ingelheim International Gmbh | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de PDE9A |
US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
EP2615089B1 (en) | 2010-09-07 | 2016-04-27 | Astellas Pharma Inc. | Pyrazoloquinoline compounds |
JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2012
- 2012-10-04 RS RS20160232A patent/RS54702B1/en unknown
- 2012-10-04 WO PCT/JP2012/075748 patent/WO2013051639A1/ja active Application Filing
- 2012-10-04 RU RU2014112931/04A patent/RU2605096C2/ru active
- 2012-10-04 TW TW101136747A patent/TWI562993B/zh active
- 2012-10-04 EP EP12837953.4A patent/EP2769980B1/en active Active
- 2012-10-04 CA CA2861795A patent/CA2861795C/en active Active
- 2012-10-04 US US13/644,745 patent/US8563565B2/en active Active
- 2012-10-04 AU AU2012319549A patent/AU2012319549B2/en active Active
- 2012-10-04 ES ES12837953.4T patent/ES2568015T3/es active Active
- 2012-10-04 MY MYPI2014700702A patent/MY167698A/en unknown
- 2012-10-04 PL PL12837953T patent/PL2769980T3/pl unknown
- 2012-10-04 BR BR112014007912-9A patent/BR112014007912B1/pt active IP Right Grant
- 2012-10-04 JP JP2013537544A patent/JP5546693B2/ja active Active
- 2012-10-04 SG SG11201400717QA patent/SG11201400717QA/en unknown
- 2012-10-04 JO JOP/2012/0302A patent/JO3116B1/ar active
- 2012-10-04 ME MEP-2016-65A patent/ME02394B/me unknown
- 2012-10-04 HU HUE12837953A patent/HUE028555T2/en unknown
- 2012-10-04 PE PE2014000408A patent/PE20141557A1/es active IP Right Grant
- 2012-10-04 DK DK12837953.4T patent/DK2769980T3/en active
- 2012-10-04 MX MX2014003800A patent/MX358149B/es active IP Right Grant
- 2012-10-04 KR KR1020147008769A patent/KR101943680B1/ko active IP Right Grant
- 2012-10-04 IN IN2463CHN2014 patent/IN2014CN02463A/en unknown
- 2012-10-04 AR ARP120103702A patent/AR088235A1/es active IP Right Grant
- 2012-10-04 SI SI201230501A patent/SI2769980T1/sl unknown
- 2012-10-04 CN CN201280046653.2A patent/CN103930423B/zh active Active
-
2013
- 2013-06-11 US US13/914,898 patent/US20130296352A1/en not_active Abandoned
-
2014
- 2014-03-19 CO CO14059034A patent/CO6910200A2/es active IP Right Grant
- 2014-03-20 IL IL231650A patent/IL231650A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02439A patent/ZA201402439B/en unknown
- 2014-04-03 CL CL2014000821A patent/CL2014000821A1/es unknown
- 2014-12-08 HK HK14112316.6A patent/HK1199018A1/zh unknown
-
2016
- 2016-03-17 HR HRP20160273TT patent/HRP20160273T1/hr unknown
- 2016-04-12 CY CY20161100302T patent/CY1117427T1/el unknown
- 2016-04-14 SM SM201600108T patent/SMT201600108B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX358149B (es) | Derivado de pirazoloquinolina. | |
PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
PH12015500209A1 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
NZ752732A (en) | Oxysterols and methods of use thereof | |
PH12017502351A1 (en) | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor | |
EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
DOP2015000289A (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo | |
IN2014MN01897A (es) | ||
ES2531324T3 (es) | Intermedio para producir un derivado de gamma-aminoácido bicíclico | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
CR20150254A (es) | Compuestos quimicos | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
ECSP13013038A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
MY178760A (en) | Monocyclic pyridine derivative | |
MX2010008818A (es) | Derivado de bicicloamina. | |
PH12015502429A1 (en) | Dicarboxylic acid compound | |
MY164007A (en) | Quinolone compound and pharmaceutical composition | |
PH12015501146A1 (en) | Hydantoin derivative | |
EA201390374A1 (ru) | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина | |
MX2011012537A (es) | Agente para el tratamiento o prevencion de enfermedades asociadas con actividad de factores neurotroficos. | |
MX2014014808A (es) | Compuestos triciclicos como inhibidores de kat ii. | |
MX2016006482A (es) | Derivado novedoso de 3-azabiciclo[3.1.0]hexano y uso del mismo para proposito medico. | |
MX355654B (es) | Derivado de paroxetina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |